KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments (2018 - 2023)

Esperion Therapeutics (ESPR) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $17.5 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Change in Acquisitions & Divestments rose 250.0% year-over-year to $17.5 million, compared with a TTM value of $17.5 million through Mar 2024, down 81.18%, and an annual FY2023 reading of $42.5 million, down 37.5% over the prior year.
  • Change in Acquisitions & Divestments was $17.5 million for Q2 2023 at Esperion Therapeutics, down from $25.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $45.9 million in Q1 2019 and bottomed at $2.2 million in Q3 2020.
  • Average Change in Acquisitions & Divestments over 4 years is $20.8 million, with a median of $23.3 million recorded in 2019.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 89.62% in 2020, then surged 250.0% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $5.0 million in 2019, then plummeted by 55.0% to $2.2 million in 2020, then skyrocketed by 1233.38% to $30.0 million in 2022, then plummeted by 41.67% to $17.5 million in 2023.
  • Business Quant data shows Change in Acquisitions & Divestments for ESPR at $17.5 million in Q2 2023, $25.0 million in Q1 2023, and $30.0 million in Q4 2022.